TY - JOUR
T1 - Models, mechanisms and clinical evidence for cancer dormancy
AU - Aguirre-Ghiso, Julio A.
N1 - Funding Information:
I apologize to those authors whose work I could not cite directly because of space constraints. I would like to thank the members of my laboratory and L. Ossowski (Mount Sinai School of Medicine) for stimulating discussions and critical reading of the manuscript. I also thank D. Schewe for discussions and help with the figures. This work is supported by a grant from the Samuel Waxman Cancer Research Foundation Tumour Dormancy Program and the NIH/National Cancer Institute grant CA109182 to J.A.A.G.
PY - 2007/11
Y1 - 2007/11
N2 - Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades. This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic. Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease. Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance. The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.
AB - Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades. This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic. Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease. Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance. The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.
UR - http://www.scopus.com/inward/record.url?scp=35548936833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35548936833&partnerID=8YFLogxK
U2 - 10.1038/nrc2256
DO - 10.1038/nrc2256
M3 - Review article
C2 - 17957189
AN - SCOPUS:35548936833
SN - 1474-175X
VL - 7
SP - 834
EP - 846
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 11
ER -
